Fosun Pharma Q3 Net Profit Climbs 15% to 10 Billion Yuan Revenue as One-Off Gains Lift Results

Shanghai Fosun Pharmaceutical said third-quarter 2026 net profit rose 15% from a year earlier, helped by one-off gains, while revenue edged up 1.4% to 10 billion yuan, or about $1.5 billion. Forbes reported the results on October 27, 2026.

Fosun Pharma's One-Off Gains and Profit Drag

Without the bump from extraordinary items, earnings would have slid 8% from a year earlier, according to the report. Profit was hurt in part by a decline in contributions from out-licensing projects and a decrease in income from associates and joint ventures, the company said.

Fosun Pharma is the main pharmaceutical arm of China's Fosun International, an investment group led by billionaire Guo Guangchang. The company was founded in 1994 and describes itself as a global pharmaceutical and healthcare group developing innovative drugs, biosimilars, cell therapies and diagnostics for oncology, infectious disease and rare diseases across more than 90 countries.

Fosun Pharma has said it plans to list Fosun Adgenvax, its 70%-owned vaccine business unit, on the Hong Kong Stock Exchange. In the first three quarters of 2026, the company spent 5.2 billion yuan on research and development, an increase of 31% from a year earlier.

Chairman Chen Yuqing said in an interview earlier this year that China had moved from a follower to a leader in global pharma. Chen said the total value of out-licensing deals for China-originated innovative drugs exceeded $13 billion in 2025, "underscoring the global recognition of China's R&D capabilities."

Fosun Pharma's Deal and Approval Record

According to akta.pro company records, Fosun Pharma signed an exclusive global option agreement with AriBio in May 2026 for AR1001, an oral PDE5 inhibitor for Alzheimer's disease in Phase 3 POLARIS-AD, with $60 million upfront and additional payments tied to $2.5 billion annual net sales milestones. In April 2026 the company signed a memorandum of understanding with Abu Dhabi-based Arcera Life Sciences for long-term collaboration in licensing, frontier technology incubation and neuroscience innovation. In February 2026 it secured European Commission approval for serplulimab (Hetronifly) as the first and only anti-PD-1 monoclonal antibody approved in the EU for first-line extensive-stage small cell lung cancer.

Fosun Pharma's Malaria Supply and Buyback

On October 21, 2026, Fosun Pharma said it had supplied over 460 million vials of artesunate for injection worldwide, saving more than 92 million patients with severe malaria, Stock Titan reported. In September 2026 the company announced an H-share repurchase plan of up to HK$1 billion, funded by proceeds from selling about 6% of Gland Pharma for roughly $294 million, FinancialContent Business Page reported. On September 4, 2026, its luvometinib tablets received NMPA approval for treating adult patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas, The Pharma Letter reported.

Fosun Adgenvax Listing Plan

Fosun Pharma has said it plans to list its 70%-owned vaccine unit Fosun Adgenvax on the Hong Kong Stock Exchange. The company has not stated a date for the listing.